PeptideStack
5.2kquestions
20kanswers
220users

How does dulaglutide at 0.25 mg weekly compare on cost per milligram across routes?

Asked 2 Nov 2025Modified 5 months agoViewed 8.9k times
13

Stated plainly: dulaglutide · 0.25 mg.

I have worked this out and I would like someone to find the error, because I suspect there is one.

My working so far, for the record, is below, and I am fairly sure the error is in the unit conversion rather than the algebra.

Is my approach right even if my number is wrong?

cost-analysis
cost-analysis

Cost arithmetic done honestly: cost per milligram after dead-space loss, list versus net price, comparing a multi-dose vial to a fixed-dose pen,…

260 questions
vendor-comparison
vendor-comparison

Side-by-side comparison of suppliers on measurable axes - independently confirmed purity and content, lead time, cold-chain handling,…

388 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
dulaglutide
dulaglutide

A once-weekly GLP-1 receptor agonist built on an Fc fusion rather than fatty-acid acylation. Use this tag for questions about the fusion-protein…

200 questions
shareeditfollowflag
PM
askedp_mkhize58k2382 Nov 2025
6Can you say what you are optimising for? Cost and confidence pull in opposite directions. – tess_amankwah 9 months ago
7Voting to keep this open — it is more specific than it first looks. – tandem_gradient 35 days ago
add a comment

5 Answers

Sorted by votes
46

0.25 mg a week is 13 mg a year and 1.1 mg in an average month — put every route on that denominator before comparing anything. Cost per milligram is the only figure that survives the comparison, because the presentations differ: a licensed pen prices a dose, a compounding pharmacy prices a vial, and a research supplier prices a mass. Divide each one's twelve-month cost by 13 mg and the three become the same number in the same unit. Then add what the cheapest route does not include — independent purity and content testing, the vials you discard, and the postage — because a route that needs testing to be trustworthy has that testing in its cost per milligram whether you account for it or not.

Start by listing every cost in the chain, since carriage, testing and wastage frequently exceed the difference in headline price.

Dead-space loss is small with fixed-needle insulin syringes — a few microlitres per draw — and substantial with detachable-needle luer syringes at 35 to 100 microlitres. Across twenty draws that is up to two millilitres of solution.

Carriage amortises across the order. Twenty-five pounds of carriage on one vial is £2.50/mg on a 10 mg vial; on ten vials it is £0.25/mg. That single term explains most of the case for larger, less frequent orders.

Syringe dead-space volumes are published per design, with fixed-needle insulin syringes under 5 microlitres and conventional luer designs at 35 microlitres or more.

Decide whether you are optimising cost or confidence before you build the model.

shareimprove this answerflag
EL
answeredesben_lykke84k1585 Feb 2026
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
30

The short version: unit price, carriage, testing, dead-space loss and wastage. The first is the one everybody compares and rarely the one that decides it.

The full calculation: (unit price + carriage share + testing share) ÷ (nominal mg × measured content fraction × (1 − dead-space and wastage fraction)). Every term after the first is routinely omitted.

On the detail: cost per milligram is the wrong metric entirely if you are optimising for confidence rather than price, and it is worth saying which one you are doing before you build the spreadsheet.

Independent testing prices at the services this community uses are published and are stable enough to model.

Larger orders reduce cost per milligram and increase exposure to a single lot, which is a real trade rather than a free win.

Larger orders are cheaper per milligram and concentrate lot risk. Price both.

shareimprove this answerflag
LT
answeredlane_transit60k4716 Feb 2026
6Thank you — the checklist format makes this actionable rather than merely correct. – w_okoye 5 months ago
add a comment
24

The honest answer is that the cheapest headline price is frequently not the cheapest outcome.

Worked example. Supplier A: £60 for a 10 mg vial, content 96 per cent, so 9.6 mg for £60, or £6.25/mg before carriage. Supplier B: £52 for the same nominal vial, content 88 per cent, so 8.8 mg for £52, or £5.91/mg. B still wins here, but the gap has narrowed from thirteen per cent on the label to five per cent in reality.

Independent testing costs roughly the price of one to two vials at the services this community uses. On a two-vial order that is a fifty to a hundred per cent surcharge; on a twenty-vial order it is five per cent.

Carriage on international consignments scales sub-linearly with weight, which is the quantitative basis for order consolidation.

Fixed-needle syringes save more peptide than most price differences do.

shareimprove this answerflag
DV
answereddead_volume56k4827 Feb 2026
3Any view on whether two lots agreeing is worth more than one lot excelling? I think it is. – e_dziedzic 7 months ago
4Same experience here, different supplier. – ellis_thorne 9 months ago
add a comment
19

Answer first: compare cost per milligram of measured peptide, not per milligram of label claim, because content varies enough to reverse a comparison.

Change one number and it reverses: if B assays at 82 per cent, that is 8.2 mg for £52, or £6.34/mg, and the cheaper vial is now the more expensive peptide.

Published content assay results across the independent services show nominal and measured content differing by one to ten per cent, which is the term that makes label-price comparisons unreliable.

The caveat is that optimising cost per milligram optimises for the wrong thing if documentation and consistency are what you actually need.

Divide by measured content, not by label claim. That is the whole correction.

shareimprove this answerflag
TO
answeredt_oyelaran79k4810 Nov 2025
14

The relevant detail is that wastage from expired reconstituted vials is a real line item and nobody includes it.

Wastage from a reconstituted vial discarded at the end of its in-use period is a genuine cost, and it is a function of the diluent volume chosen at reconstitution rather than of anything the supplier did.

The published aggregate datasets from Janoshik, Medutest and PeptideMeter are the closest thing to a systematic evidence base in this space, and the striking pattern across all three is that identity is almost always confirmed, purity is usually acceptable, and content is where the variance lives.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Include carriage and testing as per-milligram terms. They dominate small orders.

shareimprove this answerflag
EL
answeredesben_lykke84k15821 Nov 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.